To use our website in an optimal way, please activate JavaScript in your Browser.

Galileo Research Fact Sheet #94: Can Galileo Therapy improve the disability status of MS patients?

20.09.2017


This study shows the positive effects of only 8 weeks (24 session of 5*1 minutes) Galileo Therapy on muscle function, cognition and disability status in MS (Multiple Sclerosis) patients (20Hz, Position 1.5, 20° bent legs, 5 * 1 minutes, 3 session per week over 8 weeks, see also #GRFS82). The results show significant improvements in of disease related symptoms assessed by different scoring methods like PDDS (Patient Determined Disease Steps) und MSFC (Multiple Sclerosis Functional Composites) – both assessments which document the disease related disabilities. PDDS as well as the MS specific MSFC showed significant improvements of up to 18% in PDDS as well as +0.36 standard deviations (SD) in the MSFC. The average MSFC values was 0 SD at the beginning of the study and 0.36 SD at the end of the study. 0 SD is equivalent to the average disability status of the reference group, while a value of 0.36 SD means a decrease in disease related disabilities.

Therapy - MS (Multiple Sklerosis)   
#GRFS94 #GRFS


Product groups: Galileo® Therapy Systems
Topics: Muscle-Bone Relation, Concept Diagnostics & Therapy, Training & Study Support, Therapy & Prevention with Galileo®